Market Closed -
Bombay S.E.
06:00:47 2024-05-14 am EDT
|
5-day change
|
1st Jan Change
|
584.9
INR
|
+2.81%
|
|
+0.46%
|
-3.98%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
4,206
|
4,251
|
2,676
|
4,494
|
6,230
|
6,784
|
Enterprise Value (EV)
1 |
4,582
|
4,352
|
2,262
|
3,578
|
5,095
|
5,666
|
P/E ratio
|
12.1
x
|
8.73
x
|
5.2
x
|
7.22
x
|
8.98
x
|
9.31
x
|
Yield
|
0.71%
|
0.71%
|
1.12%
|
0.67%
|
0.48%
|
0.44%
|
Capitalization / Revenue
|
1.17
x
|
1.16
x
|
0.69
x
|
1.06
x
|
1.32
x
|
1.33
x
|
EV / Revenue
|
1.27
x
|
1.19
x
|
0.59
x
|
0.84
x
|
1.08
x
|
1.11
x
|
EV / EBITDA
|
8.74
x
|
6.46
x
|
3.45
x
|
4.1
x
|
5.33
x
|
6.32
x
|
EV / FCF
|
398
x
|
15.8
x
|
5.38
x
|
7.62
x
|
75.2
x
|
54.6
x
|
FCF Yield
|
0.25%
|
6.33%
|
18.6%
|
13.1%
|
1.33%
|
1.83%
|
Price to Book
|
1.88
x
|
1.58
x
|
0.85
x
|
1.2
x
|
1.44
x
|
1.35
x
|
Nbr of stocks (in thousands)
|
20,000
|
20,000
|
20,000
|
20,000
|
20,030
|
20,030
|
Reference price
2 |
210.3
|
212.6
|
133.8
|
224.7
|
311.0
|
338.7
|
Announcement Date
|
9/5/18
|
9/4/19
|
9/8/20
|
9/7/21
|
9/6/22
|
9/6/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
3,606
|
3,662
|
3,865
|
4,242
|
4,721
|
5,103
|
EBITDA
1 |
524.2
|
674
|
655.1
|
872
|
956.3
|
895.8
|
EBIT
1 |
464.3
|
608
|
583.4
|
798
|
877
|
805.5
|
Operating Margin
|
12.87%
|
16.6%
|
15.09%
|
18.81%
|
18.58%
|
15.78%
|
Earnings before Tax (EBT)
1 |
462.5
|
621.9
|
672.3
|
837.2
|
959.4
|
1,005
|
Net income
1 |
346.2
|
487.1
|
514.4
|
622.2
|
693.6
|
729
|
Net margin
|
9.6%
|
13.3%
|
13.31%
|
14.67%
|
14.69%
|
14.29%
|
EPS
2 |
17.31
|
24.36
|
25.72
|
31.11
|
34.63
|
36.40
|
Free Cash Flow
1 |
11.52
|
275.4
|
420.6
|
469.4
|
67.77
|
103.8
|
FCF margin
|
0.32%
|
7.52%
|
10.88%
|
11.07%
|
1.44%
|
2.03%
|
FCF Conversion (EBITDA)
|
2.2%
|
40.86%
|
64.2%
|
53.83%
|
7.09%
|
11.59%
|
FCF Conversion (Net income)
|
3.33%
|
56.54%
|
81.76%
|
75.45%
|
9.77%
|
14.24%
|
Dividend per Share
2 |
1.500
|
1.500
|
1.500
|
1.500
|
1.500
|
1.500
|
Announcement Date
|
9/5/18
|
9/4/19
|
9/8/20
|
9/7/21
|
9/6/22
|
9/6/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
376
|
101
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
414
|
916
|
1,136
|
1,118
|
Leverage (Debt/EBITDA)
|
0.7174
x
|
0.1491
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
11.5
|
275
|
421
|
469
|
67.8
|
104
|
ROE (net income / shareholders' equity)
|
16.6%
|
19.7%
|
17.7%
|
18.1%
|
17.4%
|
15.6%
|
ROA (Net income/ Total Assets)
|
8.89%
|
10.7%
|
9.65%
|
11.8%
|
11.1%
|
8.98%
|
Assets
1 |
3,893
|
4,566
|
5,328
|
5,294
|
6,243
|
8,122
|
Book Value Per Share
2 |
112.0
|
135.0
|
157.0
|
188.0
|
216.0
|
251.0
|
Cash Flow per Share
2 |
3.280
|
2.730
|
6.120
|
5.720
|
9.390
|
2.520
|
Capex
1 |
99
|
149
|
76.9
|
87.5
|
455
|
143
|
Capex / Sales
|
2.75%
|
4.08%
|
1.99%
|
2.06%
|
9.64%
|
2.8%
|
Announcement Date
|
9/5/18
|
9/4/19
|
9/8/20
|
9/7/21
|
9/6/22
|
9/6/23
|
|
1st Jan change
|
Capi.
|
---|
| -3.98% | 136M | | +31.06% | 682B | | +30.35% | 586B | | -3.42% | 364B | | +18.02% | 327B | | +4.27% | 285B | | +15.53% | 240B | | +10.16% | 209B | | -8.14% | 203B | | +8.12% | 165B |
Other Pharmaceuticals
|